Trials / Unknown
UnknownNCT05938426
Digital Therapeutics Research on Efficiency About Mild Cognitive Impairment Study
Digital Therapeutics (ET-101) Research on Efficiency and Safety About Mild Cognitive Impairment, Randomized, Sham Device, Assessor-blinded, Multi-center Pivotal Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Emocog Inc. · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficiency and safety of a digital therapeutics(ET-101) for mild cognitive impairment (MCI). This is a randomized, sham-controlled, assessor-blinded, 24-week parallel study. 100 MCI patients will be randomly assigned to two groups. The control group will be provided with a sham device.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ET-101 | Patients have training sessions twice a day. Each training session takes about 10\~25 minutes. Cognitive training programs include meditation, cognitive training, and cognitive testing. |
| DEVICE | Sham Device | Sham device has only cognitive function test excluding training programs. |
Timeline
- Start date
- 2023-06-08
- Primary completion
- 2024-03-31
- Completion
- 2024-06-30
- First posted
- 2023-07-10
- Last updated
- 2024-02-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05938426. Inclusion in this directory is not an endorsement.